Michael Babich

Oppenheimer said in a note on Wednesday Insys Therapeutics Inc (NASDAQ: INSY) maintains its potential long-term upside. However, the firm said it prefers to be on the sidelines for now. DoJ Investigation Resolution Awaited Analyst Derek Archila said he continues to rate Insys at Perform, as...